This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-27 and is reviewed periodically as new material appears.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
After a difficult few months at Eckartsau, the Imperial Family received aid from an unexpected source. Prince Sixtus had met King George V and appealed to him to help the Habsburgs. George was reportedly moved by the request, it being only months since his imperial relatives in Russia had been executed by revolutionaries, and promised "We will immediately do what is necessary." Several British Army officers were sent to help Charles, most notably Lieutenant-Colonel Edward Lisle Strutt, who was a grandson of Lord Belper and a former student at the University of Innsbruck. On 19 March 1919, orders were received from the War Office to "get the Emperor out of Austria without delay". With some difficulty, Strutt managed to arrange a train to Switzerland, enabling the Emperor to leave the country with dignity without having to abdicate. Charles, Zita, their children and their household left Eckartsau on 24 March escorted by a detachment of British soldiers from the Honourable Artillery Company under the command of Strutt.
Fossil deposits indicate the amiiforms included freshwater and marine species that were once widely distributed in North America, South America, Eurasia, and Africa. Today, the two species of Amia are the only remaining species in the order Amiiformes; they are demersal, freshwater piscivores, and their range is restricted to freshwater environments in North America, including much of the Eastern United States and adjacent southern Canada from the St. Lawrence River and Lake Champlain drainage of southern Ontario and Quebec westward around the Great Lakes in southern Ontario into Minnesota. Historically, their distribution in North America included the drainage basins of the Mississippi River from Quebec to northern Minnesota, the St. Lawrence-Great Lakes, including Georgian Bay, Lake Nipissing, and Simcoe, Ontario, south to the Gulf of Mexico; Atlantic and Gulf Coastal Plain from the Susquehanna River drainage in southeastern Pennsylvania to the Colorado River in Texas.
=== Applications === The triple-stranded DNA regions can be generated through the association of Triplex Forming Oligonucleotides (TFO) and Peptide Nucleic Acids (PNAs). Historically, TFO binding has been shown to inhibit transcription, replication, and protein binding to DNA. TFOs tethered to mutagens have also been shown to promote DNA damage and induce mutagenesis. Although TFO have been known to hinder transcription and replication of DNA, recent studies have shown that TFO can be utilized to mediate site specific gene modifications both in vitro and in vivo. Another recent study has also shown that TFOs can be used for suppression of oncogenes and proto-oncogenes to reduce cancer cell growth. For example, a recent study has used TFOs to reduce cellular death in hepatoma cells through the decreasing the expression of MET. PNA TFOs have the ability to enhance recombination frequencies, leading to targeted, specific editing of genes. The PNA-DNA-PNA triplex helix is able to be recognized by the cell's own DNA repair mechanism, which sensitizes the surrounding DNA for homologous recombination. In order for a site-specific PNA structure to mediate recombination within a DNA sequence, a bis-PNA structure can be coupled with a 40nt DNA fragment that is homologous to an adjacent region on the target gene. The linking of a TFO to a donor DNA strand has been shown to induce recombination of the targeted gene and the adjacent gene target region.
Sources: en.wikipedia.org
== Development == Day of Defeat began development as a third-party Half-Life modification in 1999. In 2000, the mod’s development team started releasing closed alpha versions, eventually releasing Beta 1.0, the first public version, in January 2001. In the initial release of the modification, it included only four player classes: Light Infantry, Assault Infantry, Sniper, and Heavy Weapons, with each class having unique movement characteristics. This difference, however, was removed with the release of Beta 2.0 in February 2002. Beta 2.0 also introduced a new recoil and aiming system, significantly reduced accuracy while moving, added new weapons and machine gun classes with deployable bipods, and introduced prone and sprinting mechanics, resulting in major changes to the gameplay. In July 2002, Beta 3.0 was released with a new classes based around paratrooper maps, in which players would only respawn upon the beginning of a new round. While the first versions of Day of Defeat were distributed over the internet at no cost, the rights to the game were later purchased by Valve and the modding team hired. Valve then produced a stand-alone retail version of the game, published by Activision and released in May 2003. The retail version included a number of changes from the modification, including the addition of British Army, improved graphics and fifteen maps, nine of which were completely new.
While estradiol itself has not been used clinically by intravenous injection, certain estrogen preparations such as conjugated estrogens and estramustine phosphate are available in formulations indicated for intravenous injection. Both of these medications act in part as prodrugs of estradiol. The intravenous formulation of conjugated estrogens is available at a dose of 25 mg per injection and is used in the treatment of abnormal uterine bleeding due to its ability to rapidly and temporarily enhance coagulation. It has also been used off-label to treat severe bleeding after hysteroscopic metroplasty and as an emergency contraceptive. The formulation is given in a single injection but can be repeated after 6 to 12 hours if necessary. Intravenous estramustine phosphate has a relatively long duration and, like oral estramustine phosphate, is used in the treatment of prostate cancer. Estramustine phosphate was initially introduced as an intravenous formulation and was only later introduced as an oral medication. Following introduction of the more convenient oral formulation, intravenous estramustine phosphate has largely been abandoned. The administration of large doses of estrogens intravenously has been studied.
== History == The backdoor pathway to DHT biosynthesis was discovered in early 2000s in the marsupials and later confirmed in humans. That is why the backdoor pathway of DHT biosynthesis from 17OHP can be called a marsupial pathway. This pathway is also present in other mammals, such as rats, and are studied in the other mammals as a way to better understand these pathways in humans. Marsupials, and in particular, tammar wallabies (Notamacropus eugenii) are especially useful for studying the processes of sexual differentiation and development in the context of androgen biosynthesis, because sexual differentiation in these species occurs only after birth, with testes beginning to form two days after birth and ovaries only on the eighth day after birth. This feature of post-natal early sexual differentiation allows scholars to study the influence of hormones on the body from the very beginning of the process of sexual differentiation, as well as the pathways of biosynthesis of these hormones. Tammar wallabies are particularly interesting due to the fact that all these hormones, pathways, and the ways in which hormones affect body features and growth of different organs can be studied when the organism is already born, unlike in other mammals such as rats, where sexual differentiation in a fetus occurs inside the placenta before birth.
Sources: en.wikipedia.org
=== DNA damage === Aging is the most important risk factor for cardiovascular problems. The causative basis by which aging mediates its impact, independently of other recognized risk factors, remains to be determined. Evidence has been reviewed for the key role of DNA damage in vascular aging. 8-oxoG, a common type of oxidative damage in DNA, is found to accumulate in plaque vascular smooth muscle cells, macrophages and endothelial cells, thus linking DNA damage to plaque formation. DNA strand breaks also increased in atherosclerotic plaques. Werner syndrome (WS) is a premature aging condition in humans. WS is caused by a genetic defect in a RecQ helicase that is employed in several repair processes that remove damage from DNA. WS patients develop a considerable burden of atherosclerotic plaques in their coronary arteries and aorta: calcification of the aortic valve is also frequently observed. These findings link excessive unrepaired DNA damage to premature aging and early atherosclerotic plaque development (see DNA damage theory of aging).
== Osteocyte feedback == Feedback from physical activity maintains bone mass, while feedback from osteocytes limits the size of the bone-forming unit. An important additional mechanism is secretion by osteocytes, buried in the matrix, of sclerostin, a protein that inhibits a pathway that maintains osteoblast activity. Thus, when the osteon reaches a limiting size, it deactivates bone synthesis.
=== Urogynaecological === Weakened connective tissues can lead to pelvic organ prolapse in female patients with EDS. Patients may also experience voiding difficulties, frequent urinary tract infections, and incontinence due to structural abnormalities. Pelvic girdle pain is also frequently reported. Menorrhagia, dysmenorrhea, and dyspareunia are common symptoms associated with EDS and are often mistaken for endometriosis. Excessive menstrual bleeding can sometimes be attributed to inappropriate platelet aggregation, but faulty collagen leads to weakened capillary walls, which increase the likelihood of hemorrhage. In cases of pregnancy, patients with EDS are likelier to experience complications during parturition. Post-partum hemorrhage and maternal injury, such as sporadic pelvic displacement, hip dislocation, torn and stretched ligaments, and skin tearing, can all be linked to the altered structure of connective tissues.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.